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Abstract
Introduction: A large part of research into drug addiction focuses on mesolimbic dopamine
circuitry; however, both alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and/or
kainate and dopamine D2 receptors can play a role in maintaining the established addiction.
Case presentation: We report the case of a 34-year-old man who compulsively smoked 80 to
100 cigarettes each day. After receiving treatment with topiramate and aripiprazole, his tobacco
consumption was dramatically reduced.
Conclusion: Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and/or kainate blocking
agents and a dopamine D2 receptor partial agonist may be novel instruments for nicotine abuse
disorders.
Introduction
It is generally considered that the effect of drugs of abuse
is focused towards mesolimbic dopamine (DA) reward
circuitry; this is formed by the ventral tegmental area,
which projects rostrally to the forebrain and limbic
regions, such as the nucleus accumbens, amygdala and
frontal cortex [1], and the glutamatergic neurotransmis-
sion system [2].
We report a dramatic decrease in tobacco consumption in
a patient under treatment with topiramate (an anticonvul-
sant with glutamatergic blocking properties) and aripipra-
zole (a selective DA D2 receptor partial agonist).
Case presentation
A 34-year-old man was admitted after being found uncon-
scious. He was diagnosed with metabolic coma and
admitted to an intensive care unit for 9 days. He was dis-
charged with a diagnosis of mild-moderate encephalopa-
thy of probably mixed origin (hypoglycemia and anoxia);
1 mg haloperidol and 2 mg lormetazepam at bedtime
were prescribed in addition to his usual treatment.
The patient was seen at the emergency medical service 33
days after being discharged. He was suffering from hallu-
cinosis and agitation. An increase in the haloperidol dose
up to 4 mg/day was prescribed, and the patient was
referred to a local community mental health center.
The patient was a cocaine and alcohol addict and had pre-
viously received treatments for these addictions without
success.
His past history included diabetes mellitus type I, diabetic
retinopathy, painful diabetic polyneuropathy being
treated with 800 mg gabapentin three times a day, sexual
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dysfunction, alcoholic liver disease and asthmatic bron-
chitis.
Three months later, he went to the community mental
health center with his mother, with whom he lives. As a
consequence of his condition, the patient presented with
an altered gait and mental deterioration (measured using
the Benton Visual Retention test and Weschsler Memory
Scale III). He showed much lower memory ability than
expected for a person of his age and premorbid intellec-
tual capacity. Although he had not relapsed into cocaine
and alcohol consumption, his mother related that he was
compulsively smoking about 80 to 100 cigarettes/day,
and when she tried to control and reduce his consump-
tion, his behavior became violent.
In successive consultations, the patient did not present
alterations of thought process, sensory-perceptual altera-
tions, delusional ideations, major affective disorder or
suicidal ideation.
His psychopharmacologic treatments were changed to
topiramate (beginning with 50 mg/day, and increasing by
50 mg every week up to 200 mg/day), and aripiprazole 15
mg/day to control his tobacco consumption;
lormetazepam was changed to 150 mg trazodone at bed-
time because the patient claimed to be suffering from
sleeplessness. A month later, his tobacco smoking had
decreased to fewer than 80 cigarettes/day, and after
another month, the patient was smoking 40 to 60 ciga-
rettes/day.
Discussion
The main point of this case report is that a patient who
was a heavy smoker and who was being treated with
gabapentin did not change his tobacco consumption;
however, when topiramate and aripiprazole were added,
his tobacco consumption underwent a dramatic reduc-
tion.
Topiramate is an anticonvulsant and its action mecha-
nisms include inhibition of voltage-gated Na+ and Ca+
channels and activation of gamma-aminobutyric acid
(GABA) receptors, and particularly alpha-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
and/or kainate blocking properties [3]. The AMPA recep-
tor does not seem to be implicated in addiction induction,
but it can play a role in maintaining an established addic-
tion [4]. Topiramate is currently being used to treat some
drug addictive behaviors, mainly cocaine [5], alcohol [6],
and nicotine [7] dependence.
Nicotine consumption produces an increase in DA activity
at the mesolimbic reward circuit [8]. Although researchers
have focused their main interest in the AMPA/kainate sub-
type of glutamate receptor, we suggest that aripiprazole
may play a role in tobacco control. Aripiprazole has been
investigated recently as a treatment for cocaine and alco-
hol abuse [9]. It is a partial agonist for the DA D2 receptor,
so it can be defined as a DA system stabilizer on account
of its capacity to act as an agonist DA D2 receptor in situ-
ations of low dopaminergic neurotransmission and as an
antagonist of the DA D2 receptor in excess of DA neuro-
transmission [10].
In this case, the patient had been on treatment with
gabapentin for some time owing to a painful diabetic
polyneuropathy. Like other anti-anticonvulsants, gabap-
entin has multiple action mechanisms: it inhibits presyn-
aptic voltage-gated Na+ and Ca+ channels, increases
GABAergic neurotransmission and prevents the release of
various neurotransmitters, including glutamate [2],
although it does not seem to work at the AMPA/kainate
subtype receptor, which would explain its lack of antito-
bacco effect. Other researchers think that gabapentin has
an insufficient effect on glutamate-mediated excitatory
neurotransmission, which does not contribute towards
producing a pharmacological effect [11].
The interactions between smoking and antipsychotic
medication should also be taken in account: some
patients use tobacco to lower the blood levels of antipsy-
chotic medication, particularly haloperidol, chlorpro-
mazine, olanzapine and clozapine, because smoking
increases neuroleptic metabolism by inducing the cyto-
chrome P450 1A2 isoform, and this can reduce some
extrapyramidal symptoms such as akathisia.
Conclusion
Both topiramate and aripiprazole may cause drug-seeking
behavior to disappear, and may also prevent a relapse due
to their action mechanism [4]. It needs to be noted that
this patient simultaneously presented with a mild-moder-
ate encephalopathy, and so the generalization of this use
of topiramate and aripiprazole may not be appropriate.
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